Authors

• Taro Iguchi (ORCID: https://orcid.org/0000-0002-7067-6642)
• F. Gómez-Veiga
• B. Yа. Alekseev (ORCID: https://orcid.org/0000-0002-3398-4128)
• Brad Rosbrook
• Jie Ma (ORCID: https://orcid.org/0000-0002-3900-1903)
• Andrew J. Armstrong (ORCID: https://orcid.org/0000-0001-7012-1754)
• Fabian Zohren
• Arnauld Villers (ORCID: https://orcid.org/0000-0002-6298-7758)
• Daniel Peter Petrylak (ORCID: https://orcid.org/0000-0001-6165-5797)
• Nader N. El-Chaar
• Arun Azad (ORCID: https://orcid.org/0000-0001-7350-5622)
• Russell Z. Szmulewitz (ORCID: https://orcid.org/0000-0002-1444-3617)
• Antonio Alcaraz (ORCID: https://orcid.org/0000-0003-2612-5250)
• Arnulf Stenzl (ORCID: https://orcid.org/0000-0003-4207-9928)
• Neal D. Shore (ORCID: https://orcid.org/0000-0001-5767-0548)
• Gabriel P. Haas
• Jeffrey M. Holzbeierlein

Institutions

• Kanazawa Medical University (JP)
• Pfizer (United States) (US)
• Université de Lille (FR)
• Peter MacCallum Cancer Centre (AU)
• Yale Cancer Center (US)
• University of Chicago (US)
• Hospital Clínic de Barcelona (ES)
• University of Kansas Medical Center (US)
• P.A. Hertzen Moscow Oncology Research Institute (RU)
• Complexo Hospitalario Universitario A Coruña (ES)
• Carolina Urologic Research Center (US)
• Astellas Pharma (United States) (US)
• University of Tübingen (DE)

Publication Details

Journal

JAMA Network Open

Published

2025-05-07

DOI

https://doi.org/10.1001/jamanetworkopen.2025.8751

Citations

7

Primary Topic

Prostate Cancer Treatment and Research

Type

article

Field-Weighted Citation Impact

10.63

Funders

• Pfizer
• Astellas Pharma